Clinical Professor
University of Alberta, 1984, Endocrinology Fellowship

1. Tildesley HD, Mazanderani AB, Ross SA. Effect of Internet therapeutic intervention on A1C levels in patients with type 2 diabetes treated with insulin. Diabetes Care. 2010 Aug;33(8):1738-40.

2. Szabo SM, Beusterien KM, Pleil AM, Wirostko B, Potter MJ, Tildesley H, Gonder J, Barsdorf A, Levy AR. Patient preferences for diabetic retinopathy health States. Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3387-94.

3. Mazanderani AB, Wise SJ, Tildesley HD. Apolipoprotein B levels in adults with  type 1 diabetes not receiving lipid-lowering therapy. Clin Biochem. 2009 Aug;42(12):1218-21.

4. Miller RJ, Tildesley HD, Wilcox PG, Zhang H, Kreisman SH. Sex disparities in effects of cystic fibrosis-related diabetes on clinical outcomes: a matched study. Can Respir J. 2008 Sep;15(6):291-4.

5. Tildesley HD, Aydin CM, Ignaszewski A, Strelzow JA, Yu E, Bondy G. Sulfonylurea therapy is associated with increased NT-proBNP levels in the treatment of type 2 diabetes. Int J Cardiol. 2007 Feb 14;115(3):312-7.

6. Johns K, Olynik C, Mase R, Kreisman S, Tildesley H. Gestational diabetes mellitus outcome in 394 patients. J Obstet Gynaecol Can. 2006 Feb;28(2):122-7.

7. McCormack J, Johns K, Tildesley H. Metformin’s contraindications should be contraindicated. CMAJ. 2005 Aug 30;173(5):502-4.

416 – 1033 Davie Street
Vancouver, BC V6E 1M7
phone: 6046891055
fax: 6046892955